Monitoring Huntington's disease progression through preclinical and early stages [0.03%]
从临床前阶段到早期阶段的亨廷顿舞蹈病进展监测
Chris Tang,Andrew Feigin
Chris Tang
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that typically begins in middle adulthood. The neurodegenerative process that underlies HD, however, likely begins many years before clinical diagnosi...
Ali H Rajput,Charles H Adler,Holly A Shill et al.
Ali H Rajput et al.
The pathophysiology of essential tremor (ET) remains unknown. Standard neuropathological studies have reported no consistent changes but a detailed study found neurodegeneration in all ET cases - 24% demonstrated lower brainstem Lewy body (...
OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE [0.03%]
轻中度阿尔茨海默病的优化诊断和治疗
James E Galvin
James E Galvin
Alzheimer's disease (AD) is characterized by progressive declines in cognitive function and ability to carry out activities of daily living; and the emergence and worsening of behavioral/neuropsychiatric symptoms. While there is no cure for...
Eric A Epping,Jane S Paulsen
Eric A Epping
Huntington disease (HD) has traditionally been considered a movement disorder, but cognitive and psychiatric symptoms also prominently factor into its clinical presentation. Depression is one of the most common psychiatric disturbances in H...
Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review [0.03%]
阿尔茨海默病前期认知功能评估的概念性综述
David S Knopman,Richard J Caselli
David S Knopman
Biomarker evidence and clinical observations support the hypothesis that there is a diagnosable condition termed preclinical Alzheimer's disease (AD). Recently, a workgroup convened under the auspices of the National Institute on Aging and ...
Promoting exercise in Parkinson's disease through community-based participatory research [0.03%]
基于社区参与行动的研究促进帕金森病人的体育锻炼
Mark A Hirsch,Sanjay S Iyer,Danielle Englert et al.
Mark A Hirsch et al.
Parkinson's disease (PD) is a chronic, progressive, as-of-yet incurable, neurodegenerative condition affecting the nigro-striatal dopaminergic system. Emerging evidence suggests the importance of exercise in improving the trajectory of PD. ...
Milton C Biagioni,James E Galvin
Milton C Biagioni
Disease-modifying approaches for Alzheimer's disease (AD) might be most effective when initiated very early in the course, before the pathologic burden and neuronal and synaptic degeneration make it unlikely that halting disease progression...
Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options [0.03%]
行为变异型额颞叶痴呆的治疗原则——行为管理是异质性疾病治疗的重要部分，多种手段综合施策
Gregory A Jicha,Peter T Nelson
Gregory A Jicha
There are no US FDA-approved therapies for the management of frontotemporal dementia (FTD). Evidence-based medicine that would support a FDA indication for the treatment of FTD requires large-scale, randomized, double-blind, placebo-control...